California Public Employees Retirement System raised its holdings in Haemonetics Corporation (NYSE:HAE) by 9.2% in the third quarter, HoldingsChannel.com reports. The fund owned 100,558 shares of the medical instruments supplier’s stock after buying an additional 8,458 shares during the quarter. California Public Employees Retirement System’s holdings in Haemonetics were worth $4,512,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Riverhead Capital Management LLC lifted its holdings in Haemonetics by 79.3% in the second quarter. Riverhead Capital Management LLC now owns 3,407 shares of the medical instruments supplier’s stock valued at $135,000 after acquiring an additional 1,507 shares during the period. Pacad Investment Ltd. acquired a new stake in Haemonetics in the second quarter valued at $174,000. Shelton Capital Management acquired a new stake in Haemonetics in the second quarter valued at $204,000. Cubist Systematic Strategies LLC acquired a new position in shares of Haemonetics during the 2nd quarter worth $260,000. Finally, SG Americas Securities LLC acquired a new position in shares of Haemonetics during the 3rd quarter worth $316,000.

In related news, CAO Dan Goldstein sold 4,691 shares of the business’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $54.93, for a total value of $257,676.63. Following the completion of the transaction, the chief accounting officer now owns 3,747 shares of the company’s stock, valued at approximately $205,822.71. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Willaim P. Burke sold 13,193 shares of the business’s stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $54.04, for a total transaction of $712,949.72. Following the completion of the transaction, the chief financial officer now directly owns 27,227 shares of the company’s stock, valued at approximately $1,471,347.08. The disclosure for this sale can be found here. Insiders sold a total of 54,486 shares of company stock valued at $3,050,827 in the last three months. 1.20% of the stock is currently owned by corporate insiders.

Several research analysts have recently issued reports on HAE shares. Morgan Stanley reaffirmed an “equal weight” rating and set a $43.00 price target (up previously from $38.00) on shares of Haemonetics in a research note on Friday, October 6th. Zacks Investment Research raised Haemonetics from a “hold” rating to a “buy” rating and set a $52.00 price target for the company in a research note on Wednesday, October 25th. Barrington Research lifted their price target on Haemonetics from $48.00 to $57.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 8th. Craig Hallum reaffirmed a “hold” rating and set a $50.00 price target (up previously from $40.00) on shares of Haemonetics in a research note on Wednesday, November 8th. Finally, Raymond James Financial raised Haemonetics from an “underperform” rating to a “market perform” rating in a research note on Tuesday, January 2nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $58.83.

Haemonetics Corporation (HAE) opened at $63.39 on Wednesday. The stock has a market capitalization of $3,350.00, a price-to-earnings ratio of 905.57, a PEG ratio of 4.71 and a beta of 0.99. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.51 and a current ratio of 2.17. Haemonetics Corporation has a one year low of $36.44 and a one year high of $63.90.

Haemonetics (NYSE:HAE) last announced its earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.07. Haemonetics had a net margin of 0.50% and a return on equity of 11.16%. The firm had revenue of $225.40 million during the quarter, compared to the consensus estimate of $219.12 million. During the same quarter in the previous year, the company posted $0.38 EPS. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. research analysts forecast that Haemonetics Corporation will post 1.7 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://theolympiareport.com/2018/01/10/haemonetics-corporation-hae-holdings-raised-by-california-public-employees-retirement-system.html.

Haemonetics Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.